Latest Immunogenicity Stories
The Webinar on November 12, 2014 will focus on two diverse approaches for using automated microscopy and image analysis to measure different and specific indicators of cellular stress leading
PROVIDENCE, R.I., Oct.
Full Article Here: http://bit.ly/CHOPPI_PR PROVIDENCE, R.I., July 8, 2014 /PRNewswire/ -- A Public-private partnership resulted in the development of a new web-based tool that will
-- 3SBio's pegsiticase has shown a promising efficacy and safety profile in early clinical trials and Selecta and 3SBio plan to advance clinical studies of pegsiticase-based treatments for refractory
In vivo T cell active immunotherapy generated from DCVex(TM) platform SEATTLE and SOUTH SAN FRANCISCO, Calif., June 5, 2014 /PRNewswire/ -- Immune Design, a clinical-stage immunotherapy
LONDON, May 23, 2014 /PRNewswire/ -- New Company Created to be a Leading Provider of Technologies and Services to Enable Better Biopharmaceuticals
Proprietary "Smart Antibodies" Allow for Selective Activation in Cancerous Tissues SAN DIEGO, April 30, 2014 /PRNewswire/ -- BioAtla, a global biotechnology company focused on
DUBLIN, April 17, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/fclw7g/global_hemophilia) has announced the addition of the "Global
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.